Curocell

Curocell, founded in 2016 and headquartered in South Korea, is a cutting-edge company in the biopharma and biotechnology sectors. The company's slogan, "Fight against hopelessness," underscores its mission to revolutionize cancer treatment through the development of innovative CAR-T therapies.

Curocell focuses on unleashing the body's immune system using broad-spectrum CAR-T technologies targeting both blood and solid cancers. The company's distinctive approach involves programmed T cell product candidates that incorporate T cell modifying technology, aiming to overcome immune suppression and deliver greater efficacy than traditional CAR-T therapies.

The company attracted a significant KRW36.00B Venture Round investment on 04 January 2022, with support from notable investors including DS Asset Management, Ryukyung PSG, JX Partners, Seoul Investment Partners, Quad Asset Management, Widwin Investment, Moonchase Asset Management, Stick Ventures, and SK Plasma. These investments signal strong confidence in Curocell's innovative approach and potential market impact.